Moreover, because cancer cells frequently display high rates of aerobic glycolysis, in comparison to their nontransformed counterparts, the recently published hypoglycemic impact of CHL [60], combined with the possible applications of 2-DG in anticancer therapies, further supports the theory that inhibiting G6PT functions in cancer cells could decrease tumor progression. Here, SLC37A4 is linked to cancer.